Agenus Revenue 2010-2022 | AGEN

Agenus revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Agenus Annual Revenue
(Millions of US $)
2021 $296
2020 $88
2019 $150
2018 $37
2017 $43
2016 $23
2015 $25
2014 $7
2013 $3
2012 $16
2011 $3
2010 $3
2009 $3
Agenus Quarterly Revenue
(Millions of US $)
2022-09-30 $23
2022-06-30 $21
2022-03-31 $26
2021-12-31 $20
2021-09-30 $253
2021-06-30 $11
2021-03-31 $12
2020-12-31 $31
2020-09-30 $15
2020-06-30 $27
2020-03-31 $15
2019-12-31 $35
2019-09-30 $20
2019-06-30 $16
2019-03-31 $80
2018-12-31 $6
2018-09-30 $13
2018-06-30 $16
2018-03-31 $2
2017-12-31 $8
2017-09-30 $3
2017-06-30 $4
2017-03-31 $27
2016-12-31 $6
2016-09-30 $4
2016-06-30 $7
2016-03-31 $6
2015-12-31 $8
2015-09-30 $7
2015-06-30 $6
2015-03-31 $4
2014-12-31 $2
2014-09-30 $2
2014-06-30 $3
2014-03-31 $1
2013-12-31 $0
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $1
2012-09-30 $1
2012-06-30 $1
2012-03-31 $13
2011-12-31 $1
2011-09-30 $1
2011-06-30 $1
2011-03-31 $1
2010-12-31 $1
2010-09-30 $1
2010-06-30 $1
2010-03-31 $1
2009-12-31 $1
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.777B $0.296B
Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Biohaven (BHVN) United States $1.266B 0.00
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00